Research outputs, reports, policy briefs and knowledge products from KIU scholars and partners.
Scholarly Work
Search peer-reviewed articles, reports, books, policy briefs and other scholarly outputs by KIU researchers and collaborators.
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 82-87
Sickle cell disease (SCD) is a monogenic hematologic disorder that causes significant morbidity and mortality worldwide, disproportionately affecting populations of African, Indian, Middle Eastern, and Mediterranean ancestry. Whole-exome sequencing (WES) offe...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 74-81
Advances in genomic medicine have enabled the emergence of precision public health, with polygenic risk scores (PRS) offering novel tools for population-level risk stratification and intervention. Alzheimer’s disease (AD), the most prevalent neurodegenerative...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 70-73
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with early detection critical to improving outcomes. Liquid biopsy genomics offers a minimally invasive approach to detect tumor-derived analytes in biofluids, provid...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 62-69
Timely and accurate detection of Mycobacterium tuberculosis (Mtb) remains a cornerstone of global tuberculosis (TB) control. Traditional diagnostic tools face limitations, including delayed results, variable sensitivity, and restricted access in resource-limi...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 53-61
Stroke remains a leading cause of mortality and disability worldwide, with both monogenic and polygenic genetic determinants contributing to individual and population risk. Population genomics provides a transformative approach to understanding these genetic...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 46-52
Familial hypercholesterolemia (FH) is a common inherited lipid disorder associated with markedly elevated cholesterol levels and a substantially increased risk of premature cardiovascular disease. Advances in population genomics, including biobank sequencing,...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 38-45
Polygenic risk scores (PRS) are increasingly used to estimate genetic susceptibility to complex diseases such as type 2 diabetes (T2D). However, most PRS models are derived from genome-wide association studies conducted primarily in European populations, rais...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 30-37
Pharmacogenomics leverages genomic information to optimize drug therapy, improving efficacy and minimizing toxicity in oncology patients. Whole-exome sequencing (WES) provides a comprehensive platform for identifying clinically actionable variants in germline...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 20-29
Pharmacogenomics has emerged as a cornerstone of precision medicine, enabling safer and more effective prescribing through the identification of genetic determinants of drug response. Proteogenomics extends this approach by incorporating protein expression, m...
2026 | RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY | Pp. 9-19
Pharmacogenomics and polygenic risk scores (PRS) offer transformative potential for precision medicine by tailoring prevention, diagnostics, and treatment strategies to individual genetic profiles. National Health Insurance (NHI) systems provide an optimal fr...